Skip to main content
SpringerLink
Log in

The Role of Botulinum Toxins in Treatment of Brain and Spinal Cord Injury Symptoms

  • Chapter
  • First Online:
Botulinum Toxin Treatment in Clinical Medicine

  • 1012 Accesses

Abstract

Traumatic brain and spinal cord injury cause a variety of symptoms that are amenable to botulinum neurotoxin (BoNT) treatment. These symptoms, spasticity; types of bladder dysfunction, movement disorders, and neuropathic pain are discussed in this chapter. The evidence-based literature on the efficacy of BoNT therapy for brain and spinal cord trauma-related symptoms is provided using the efficacy guidelines of the American Academy of Neurology.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Lagbas C, et al. Traumatic brain injury related hospitalization and mortality in California. Biomed Res Int. 2013;2013:143092.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Thurman DJ, et al. Traumatic brain injury in the United States: a public health perspective. J Head Trauma Rehabil. 1999;14(6):602–15.

    Article  CAS  PubMed  Google Scholar 

  3. Schneier AJ, et al. Incidence of pediatric traumatic brain injury and associated hospital resource utilization in the United States. Pediatrics. 2006;118(2):483–92.

    Article  PubMed  Google Scholar 

  4. McKinlay A, et al. Prevalence of traumatic brain injury among children, adolescents and young adults: prospective evidence from a birth cohort. Brain Inj. 2008;22(2):175–81.

    Article  CAS  PubMed  Google Scholar 

  5. Segalowitz SJ, Brown D. Mild head injury as a source of developmental disabilities. J Learn Disabil. 1991;24(9):551–9.

    Article  CAS  PubMed  Google Scholar 

  6. Body C, Leathem J. Incidence and aetiology of head injury in a New Zealand adolescent sample. Brain Inj. 1996;10(8):567–74.

    Article  CAS  PubMed  Google Scholar 

  7. Roozenbeek B, Maas AIR, Menon DK. Changing patterns in the epidemiology of traumatic brain injury. Nat Rev Neurol. 2013;9(4):231–6.

    Article  PubMed  Google Scholar 

  8. Patel A, et al. Quality of the development of traumatic brain injury clinical practice guidelines: a systematic review. PLoS One. 2016;11(9):e0161554.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Song SY, et al. Analysis of mortality and epidemiology in 2617 cases of traumatic brain injury: Korean Neuro-Trauma Data Bank System 2010–2014. J Korean Neurosurg Soc. 2016;59(5):485–91.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Faul M, et al. Traumatic brain injury in the United States. Atlanta, GA: National Center for Injury Prevention and Control, Centers for disease Control and Prevention; 2010.

    Google Scholar 

  11. Marshall LF. Head injury: recent past, present, and future. Neurosurgery. 2000;47(3):546–61.

    CAS  PubMed  Google Scholar 

  12. Coronado VG, et al. Surveillance for traumatic brain injury-related deaths: United States, 1997–2007. US Department of Health and Human Services, Centers for Disease Control and Prevention: Atlanta; 2011.

    Google Scholar 

  13. Coronado VG, et al. Trends in traumatic brain injury in the US and the public health response: 1995–2009. J Saf Res. 2012;43(4):299–307.

    Article  Google Scholar 

  14. Gracies JM. Pathophysiology of spastic paresis. I: paresis and soft tissue changes. Muscle Nerve. 2005;31(5):535–51.

    Article  PubMed  Google Scholar 

  15. Moeini-Naghani I, Hashemi-Zonouz T, Jabbari B. Botulinum toxin treatment of spasticity in adults and children. Semin Neurol. 2016;36(1):64–72.

    Article  PubMed  Google Scholar 

  16. Gracies JM. Pathophysiology of spastic paresis. II: emergence of muscle overactivity. Muscle Nerve. 2005;31(5):552–71.

    Article  PubMed  Google Scholar 

  17. Schindler-Ivens S, Shields RK. Low frequency depression of H-reflexes in humans with acute and chronic spinal-cord injury. Exp Brain Res. 2000;133(2):233–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Heckman CJ, Gorassini MA, Bennett DJ. Persistent inward currents in motoneuron dendrites: implications for motor output. Muscle Nerve. 2005;31(2):135–56.

    Article  CAS  Google Scholar 

  19. Kitzman P. Alteration in axial motoneuronal morphology in the spinal cord injured spastic rat. Exp Neurol. 2005;192(1):100–8.

    Article  PubMed  Google Scholar 

  20. Bose P, Hou J, Thompson FJ. Traumatic brain injury (TBI)-induced spasticity: neurobiology, treatment, and rehabilitation. In: Kobeissy FH, editor. Brain neurotrauma: molecular, neuropsychological, and rehabilitation aspects. Boca Raton, FL: CRC Press/Taylor & Francis; 2015.

    Google Scholar 

  21. Bose P, et al. Effects of acute intrathecal baclofen in an animal model of TBI-induced spasticity, cognitive, and balance disabilities. J Neurotrauma. 2013;30(13):1177–91.

    Article  PubMed  Google Scholar 

  22. Brown EA, Schütz SG, Simpson DM. Botulinum toxin for neuropathic pain and spasticity: an overview. Pain. 2014;4(2):129–51.

    Google Scholar 

  23. Gracies J-M, et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial. Lancet Neurol. 2015;14(10):992–1001.

    Article  CAS  PubMed  Google Scholar 

  24. Burbaud P, et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry. 1996;61(3):265–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Yablon SA, et al. Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury an open-labeled trial. Neurology. 1996;47(4):939–44.

    Article  CAS  PubMed  Google Scholar 

  26. Simpson DM, et al. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry. 2009;80(4):380–5.

    Article  CAS  PubMed  Google Scholar 

  27. Gronseth G, French J. Invited article: practice parameters and technology assessments what they are, what they are not, and why you should care. Neurology. 2008;71(20):1639–43.

    Article  PubMed  Google Scholar 

  28. Fietzek U, et al. Early botulinum toxin treatment for spastic pes equinovarus—a randomized double-blind placebo-controlled study. Eur J Neurol. 2014;21(8):1089–95.

    Article  CAS  PubMed  Google Scholar 

  29. Gracies J-M, et al. Botulinum toxin type B in the spastic arm: a randomized, double-blind, placebo-controlled, preliminary study. Arch Phys Med Rehabil. 2014;95(7):1303–11.

    Article  PubMed  Google Scholar 

  30. Smith S, et al. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil. 2000;14(1):5–13.

    Article  CAS  PubMed  Google Scholar 

  31. Pavesi G, et al. Botulinum toxin type A in the treatment of upper limb spasticity among patients with traumatic brain injury. J Neurol Neurosurg Psychiatry. 1998;64(3):419.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Siddall PJ, Finnerup NB. Pain following spinal cord injury. Handb Clin Neurol. 2006;81:689–703.

    Article  PubMed  Google Scholar 

  33. Pertovaara A. The noradrenergic pain regulation system: a potential target for pain therapy. Eur J Pharmacol. 2013;716(1):2–7.

    Article  CAS  PubMed  Google Scholar 

  34. Lemmens S, et al. Alpha-Adrenoceptor modulation in central nervous system trauma: pain, spasms, and paralysis—an unlucky triad. Med Res Rev. 2015;35(4):653–77.

    Article  CAS  PubMed  Google Scholar 

  35. Namdari S, et al. Shoulder tenotomies to improve passive motion and relieve pain in patients with spastic hemiplegia after upper motor neuron injury. J Shoulder Elb Surg. 2011;20(5):802–6.

    Article  Google Scholar 

  36. Nampiaparampil DE. Prevalence of chronic pain after traumatic brain injury: a systematic review. JAMA. 2008;300(6):711–9.

    Article  CAS  PubMed  Google Scholar 

  37. Jabbari B. Botulinum toxin treatment of pain disorders. New York: Springer; 2015.

    Book  Google Scholar 

  38. Lew HL, et al. Characteristics and treatment of headache after traumatic brain injury: a focused review. Am J Phys Med Rehabil. 2006;85(7):619–27.

    Article  PubMed  Google Scholar 

  39. Lenaerts ME. Post-traumatic headache: from classification challenges to biological underpinnings. Cephalalgia. 2008;28(1 suppl):12–5.

    Article  PubMed  Google Scholar 

  40. Seifert T. Post-traumatic headache therapy in the athlete. Curr Pain Headache Rep. 2016;20(6):1–9.

    Article  Google Scholar 

  41. Holtkamp MD, Grimes J, Ling G. Concussion in the military: an evidence-base review of mTBI in US military personnel focused on posttraumatic headache. Curr Pain Headache Rep. 2016;20(6):1–6.

    Article  Google Scholar 

  42. Theeler BJ, Flynn FG, Erickson JC. Headaches after concussion in US soldiers returning from Iraq or Afghanistan. Headache. 2010;50(8):1262–72.

    Article  PubMed  Google Scholar 

  43. Yerry JA, Kuehn D, Finkel AG. Onabotulinum toxin a for the treatment of headache in service members with a history of mild traumatic brain injury: a cohort study. Headache. 2015;55(3):395–406.

    Article  PubMed  Google Scholar 

  44. Blumenfeld A, et al. Method of injection of OnabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50(9):1406–18.

    Article  PubMed  Google Scholar 

  45. Jabbari B. History of botulinum toxin treatment in movement disorders. Tremor Other Hyperkinet Mov. 2016;6:394.

    Google Scholar 

  46. Krause T, et al. Dantrolene—a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004;59(4):364–73.

    Article  CAS  PubMed  Google Scholar 

  47. Krauss JK, Trankle R, Kopp K-H. Post-traumatic movement disorders in survivors of severe head injury. Neurology. 1996;47(6):1488–92.

    Article  CAS  PubMed  Google Scholar 

  48. Krauss JK, Tränkle R, Kopp KH. Posttraumatic movement disorders after moderate or mild head injury. Mov Disord. 1997;12(3):428–31.

    Article  CAS  PubMed  Google Scholar 

  49. Kemp S, et al. Delayed-onset focal dystonia of the leg secondary to traumatic brain injury. J Clin Neurosci. 2012;19(6):916–7.

    Article  CAS  PubMed  Google Scholar 

  50. Spiegl UJ et al. Antispastic therapy with botulinum toxin type A in patients with traumatic spinal cord lesion. GMS Interdiscip Plast Reconstr Surg DGPW 2014;3:Doc14.

    Google Scholar 

  51. Dario A, Tomei G. A benefit-risk assessment of baclofen in severe spinal spasticity. Drug Saf. 2004;27(11):799–818.

    Article  CAS  PubMed  Google Scholar 

  52. Gorgey AS, et al. Relationship of spasticity to soft tissue body composition and the metabolic profile in persons with chronic motor complete spinal cord injury. J Spinal Cord med. 2010;33(1):6–15.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Holtz KA, et al. The prevalence and effect of problematic spasticity following traumatic spinal cord injury. Arch Phys med Rehabil. 2016;98(6):1132–8.

    Article  PubMed  Google Scholar 

  54. Opara J, Hordyńska E, Swoboda A. Effectiveness of botulinum toxin A in the treatment of spasticity of the lower extremities in adults-preliminary report. Ortop Traumatol Rehabil. 2006;9(3):277–85.

    Google Scholar 

  55. Marciniak C, Rader L, Gagnon C. The use of botulinum toxin for spasticity after spinal cord injury. Am J Phys Med Rehabil. 2008;87(4):312–7. quiz 318–20, 329

    Article  PubMed  Google Scholar 

  56. Bernuz B, et al. Botulinum toxin effect on voluntary and stretch reflex-related torque produced by the quadriceps an isokinetic pilot study. Neurorehabil Neural Repair. 2012;26(5):542–7.

    Article  PubMed  Google Scholar 

  57. Goldmark E, Niver B, Ginsberg DA. Neurogenic bladder: from diagnosis to management. Curr Urol Rep. 2014;15(10):1–8.

    Article  Google Scholar 

  58. Peyronnet B, et al. Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin a (Dysport®) 750 U in the management of neurogenic detrusor overactivity: a case control study. Neurourol Urodyn. 2017;36(3):734–9.

    Article  CAS  PubMed  Google Scholar 

  59. Smith CP, Chancellor MB. Botulinum toxin to treat neurogenic bladder. Semin Neurol. 2016;36(1):5–9.

    Article  PubMed  Google Scholar 

  60. Denys P, et al. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport®(abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): a randomised placebo-controlled phase IIa study. Neurourol Urodyn. 2016;36(2):457–62.

    Article  PubMed  Google Scholar 

  61. Huynh Le Maux A, et al. Does reduction of number of Intradetrusor injection sites of aboBoNTA (Dysport®) impact efficacy and safety in a rat model of neurogenic detrusor Overactivity? Toxins. 2015;7(12):5462–71.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Stoffel JT. Detrusor sphincter dyssynergia: a review of physiology, diagnosis, and treatment strategies. Transl Androl Urol. 2016;5(1):127.

    PubMed  PubMed Central  Google Scholar 

  63. Andresen SR, et al. Pain, spasticity and quality of life in individuals with traumatic spinal cord injury in Denmark. Spinal Cord. 2016;54(11):973–9.

    Article  CAS  PubMed  Google Scholar 

  64. Bryce TN, et al. International spinal cord injury pain (ISCIP) classification: part 2. Initial validation using vignettes. Spinal Cord. 2012;50(6):404–12.

    Article  CAS  PubMed  Google Scholar 

  65. Teasell RW, et al. A systematic review of pharmacologic treatments of pain after spinal cord injury. Arch Phys Med Rehabil. 2010;91(5):816–31.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Jabbari B, Maher N, Difazio MP. Botulinum toxin A improved burning pain and allodynia in two patients with spinal cord pathology. Pain Med. 2003;4(2):206–10.

    Article  PubMed  Google Scholar 

  67. Han ZA, Song DH, Chung ME. Effect of subcutaneous injection of botulinum toxin A on spinal cord injury-associated neuropathic pain. Spinal Cord. 2014;52:S5–6.

    Article  PubMed  Google Scholar 

  68. Han ZA, et al. Botulinum toxin type A for neuropathic pain in patients with spinal cord injury. Ann Neurol. 2016;79(4):569–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Hui C, Keji X, Chonghe J, Ping T, Rubiao O, Jianweng Z, Xiangrong D, Liling Z, Maping H, Qingqing L, Qiuling L, Jiebing H, Tanghai H. Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity. Spinal Cord. 2015;54(1):46–50.

    Google Scholar 

  70. Sussman D, Patel V, Del Popolo G, Lam W, Globe D, Pommerville P. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn. 2013;32(3):242–9.

    Google Scholar 

  71. Ginsberg D, Cruz F, Herschorn S, Gousse A, Keppenne V, Aliotta P, Sievert KD, Brin MF, Jenkins B, Thompson C, Lam W, Heesakkers J, Haag-Molkenteller C. Onabotulinumtoxin A is effective in patients with urinary incontinence due to neurogenic detrusor activity regardless of concomitant anticholinergic use or neurologic etiology. Adv Ther. 2013;30(9):819–33.

    Google Scholar 

  72. Chancellor MB, Patel V, Leng WW, Shenot PJ, Lam W, Globe DR, Loeb AL, Chapple CR. Onabotulinumtoxin A improves quality of life in patients with neurogenic detrusor overactivity. Neurology. 2013;81(9):841–8.

    Google Scholar 

  73. Ginsberg D, Gousse A, Keppenne V, Sievert K-D, Thompson C, Lam W, Brin MF, Jenkins B, Haag-Molkenteller C. Phase 3 efficacy and tolerability study of onabotulinumtoxina for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187(6):2131–9.

    Google Scholar 

  74. Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, Daniell G, Heesakkers J, Haag-Molkenteller C. Efficacy and safety of onabotulinumtoxina in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(4):742–50.

    Google Scholar 

  75. Zwibel HL, Smrtka J. Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care. 2011;17:S139–45.

    Google Scholar 

  76. Reitz A, Stöhrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, Burgdörfer H, Göcking K, Madersbacher H, Schumacher S, Richter R, von Tobel J, Schurch B. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol. 2004;45(4):510–5.

    Google Scholar 

  77. Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB. Botulinum-A toxin as a treatment of detruosor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol. 1996;155(3):1023–9.

    Article  CAS  PubMed  Google Scholar 

  78. de Sze M, Petit H, Gallien P, de Sze M-P, Joseph P-A, Mazaux J-M, Barat M. Botulinum A toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol. 2002;42(1):56–62.

    Google Scholar 

  79. Kuo H-C. Satisfaction with urethral injection of botulinum toxin A for detrusor sphincter dyssynergia in patients with spinal cordlesion. Neurourol Urodyn. 2008;27(8):793–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiology and Biomedical Imaging, Yale University, New Haven, CT, USA

    Taraneh Hashemi-Zonouz M.D.

  2. Department of Neurology, Yale University, New Haven, CT, USA

    Bahman Jabbari M.D., FAAN

Authors
  1. Taraneh Hashemi-Zonouz M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bahman Jabbari M.D., FAAN
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Taraneh Hashemi-Zonouz M.D. .

Editor information

Editors and Affiliations

  1. Emeritus Professor of Neurology, Yale University, New Haven, Connecticut, USA

    Bahman Jabbari

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Hashemi-Zonouz, T., Jabbari, B. (2018). The Role of Botulinum Toxins in Treatment of Brain and Spinal Cord Injury Symptoms. In: Jabbari, B. (eds) Botulinum Toxin Treatment in Clinical Medicine. Springer, Cham. https://doi.org/10.1007/978-3-319-56038-0_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56038-0_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56037-3

  • Online ISBN: 978-3-319-56038-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation